At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Ann Marie Navar evaluates the benefits and safety profile of PCSK9 inhibitors in clinical practice.
Questions:
1. What has the FOURIER trial taught us about the benefits of PCSK9 inhibitors in people with diabetes? (0:04)
2. What adverse events are associated with the use of PCSK9 inhibitors? (1:43)
3. How do you balance the glucose-raising action of PCSK9 inhibitors with the blood lipid benefits? (2:50)
4. What factors would you consider when deciding whether to prescribe PCSK9 inhibitors to a patient with diabetes? (4:08)
5. What presentations are you most looking forward to at EASD? (5:20)
Ann Marie Navar is consulting for and has received research support from Janssen, Amgen, Regeneron, Sanofi, and Amarin. Also consulting for AstraZeneca and Novo Nordisk.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
